BSc (Hons) (Glasgow, 1977); PhD (Glasgow, 1980)
Senior Research Fellow
- About
-
- Email Address
- c.harrington@abdn.ac.uk
- Telephone Number
- +44 (0)1224 438563
- Office Address
Liberty Building, Institute of Medical Sciences, Foresterhill Road, Aberdeen AB25 2ZP United Kingdom
- School/Department
- School of Medicine, Medical Sciences and Nutrition
Biography
Charlie Harrington graduated in Microbiology from Glasgow University where he developed an interest in chemical microbiology and the study of microbial cell walls. He completed his PhD working with Dr Julia Douglas on cell wall synthesis in yeast and followed with a one-year NIH-funded Fellowship with Dr Wilf Arnold in Kansas City, Missouri studying enzymes within the yeast cell envelope. After this, Charlie joined Professor Sir James Baddiley in the Department of Biochemistry at the University of Cambridge as a Research Fellow, where he spent four years investigating the synthesis of bacterial cell wall polymers. Dr Harrington then spent over two years at Murex Medical Research Ltd., Cambridge, developing diagnostic tests for microbial diseases, including methicillin-resistant Staphylococcus aureus and sexually transmitted diseases. This combined monoclonal antibody technology with his knowledge of the microbial cell surface.
In 1988, he joined Claude Wischik working at the Medical Research Council’s Laboratory of Molecular Biology. Working in the Cambridge Brain Bank Laboratory over a period of 10 years. During this time, Wischik, Harrington and colleagues developed an assay for screening agents having the potential to prevent the tau pathology that is the hallmark of Alzheimer’s disease. Charlie moved with Professor Wischik, in 1998, to the University of Aberdeen, where he was appointed as a Senior Research Fellow.
The Alzheimer's research was translated to the clinic, through a spin-out company, TauRx Therapeutics, who are conducting phase 3 trials of hydromethylthionine. Dr Harrington is Chief Scientific Officer for TauRx Therapeutics Ltd responsible for the non-clinical activities of the company.
Qualifications
- BSc (Hons) Microbiology1977 - University of Glasgow
- PhD Microbiology1980 - University of Glasgow
Latest Publications
Inhibiting disulphide bonding in truncated tau297-391 results in enhanced self-assembly of tau into seed-competent assemblies
ACS Chemical NeuroscienceContributions to Journals: ArticlesBlood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force
Journal of Prevention of Alzheimer's Disease, vol. 9, no. 4, pp. 569-579Contributions to Journals: ArticlesSystematic gait analysis in alpha-synuclein transgenic line 62 mice using the CatWalk
Behavioural Brain Research, vol. 496, 115819Contributions to Journals: ArticlesA key region of Tau that is able to drive assembly and modulate inhibition by Hydromethylthionine
Journal of Molecular Biology, vol. 437, no. 17, 169231Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/j.jmb.2025.169231
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstreams/7a09658e-98e2-46e0-b61c-ea4a48f823ab/download
- [ONLINE] View publication in Scopus
Proteomic and non-proteomic changes of presynaptic proteins in animal models of Alzheimer’s disease: A meta-analysis 2015-2023
Journal of Alzheimer's Disease, vol. 107, no. 2, pp. 452-476Contributions to Journals: Articles
- Research
-
Research Overview
Dr Harrington has research interests in the neurodegenerative diseases and, in particular, Alzheimer’s disease. His main focus has been on the biology of tau protein in aging and in Alzheimer’s disease. Dr Harrington’s research is aimed at diseases that are characterised by protein aggregation and methods by which these processes might be prevented.
- Publications
-
Page 2 of 3 Results 51 to 100 of 107
Cysteine-independent inhibition of Alzheimer's disease-like paired helical filament assembly by leuco-methylthioninium (LMT)
Journal of Molecular Biology, vol. 430, no. 21, pp. 4119-4131Contributions to Journals: ArticlesModeling Prion-Like Processing of Tau Protein in Alzheimer's Disease for Pharmaceutical Development
Journal of Alzheimer's Disease, vol. 62, no. 3, pp. 1287-1303Contributions to Journals: ArticlesAlpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease
Behavioural Brain Research, vol. 339, pp. 153-168Contributions to Journals: ArticlesA Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases α-Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy
Frontiers in Molecular Neuroscience, vol. 10, 447Contributions to Journals: ArticlesPotential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial
Journal of Alzheimer's Disease, vol. 61, no. 1, pp. 435-457Contributions to Journals: Articles- [ONLINE] https://www.j-alz.com/vol61-1
- [ONLINE] DOI: https://doi.org/10.3233/JAD-170560
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstreams/079493ad-ead6-4304-99fe-22d4d2025820/download
Alzheimer's Disease-like Paired Helical Filament Assembly from Truncated Tau Protein Is Independent of Disulfide Crosslinking
Journal of Molecular Biology, vol. 429, no. 23, pp. 3650-3665Contributions to Journals: ArticlesLMTM DECREASES α-SYNUCLEIN PATHOLOGY AND REDUCES BEHAVIOURAL DEFECTS IN α-SYNUCLEIN TRANSGENIC MICE
Alzheimer's and Dementia, vol. 13, no. 7 Suppl., pp. P945-P945Contributions to Journals: Abstracts- [ONLINE] DOI: https://doi.org/10.1016/j.jalz.2017.06.1854
Monoaminergic Neuropathology in Alzheimer's disease
Progress in Neurobiology, vol. 151, pp. 101-138Contributions to Journals: ArticlesAssays for the Screening and Characterization of Tau Aggregation Inhibitors
Tau Protein: Methods and Protocols. Smet-Nocca, C. (ed.). Springer, pp. 129-140, 12 pagesChapters in Books, Reports and Conference Proceedings: Chapters (Peer-Reviewed)- [ONLINE] DOI: https://doi.org/10.1007/978-1-4939-6598-4_8
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial
The Lancet, vol. 388, no. 10062, pp. 2873-2884Contributions to Journals: ArticlesInhibition of Tau Aggregation as a Basis for Treatment and Prevention of Alzheimer's Disease
Developing Therapeutics for Alzheimer's Disease: Progress and Challenges. Wolfe, M. S. (ed.). Elsevier Inc., pp. 385-436, 52 pagesChapters in Books, Reports and Conference Proceedings: Chapters- [ONLINE] DOI: https://doi.org/10.1016/B978-0-12-802173-6.00015-0
- [ONLINE] View publication in Scopus
Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer's Disease
Biomolecules, vol. 6, no. 2, pp. 1-19Contributions to Journals: ArticlesTau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies
Biomolecules, vol. 6, no. 1, 6Contributions to Journals: Review articles- [ONLINE] DOI: https://doi.org/10.3390/biom6010006
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstreams/033fbdcb-c092-4ef5-b49d-2928ba7ed3db/download
- [ONLINE] View publication in Scopus
Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer’s disease and frontotemporal lobar degeneration
Cellular and Molecular Life Sciences, vol. 72, no. 11, pp. 2199-2222Contributions to Journals: ArticlesEffects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models
Behavioural Pharmacology, vol. 26, no. 4, pp. 353-368Contributions to Journals: ArticlesCellular Models of Aggregation-Dependent Template-Directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer's Disease
The Journal of Biological Chemistry, vol. 290, no. 17, pp. 10862-10875Contributions to Journals: ArticlesThe relationship between truncation and phosphorylation at the C-terminus of tau protein in the paired helical filaments of Alzheimer's disease
Frontiers in Neuroscience, vol. 9, 33Contributions to Journals: ArticlesTau Aggregation Inhibitor Therapy: An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Disease
Journal of Alzheimer's Disease, vol. 44, no. 2, pp. 705-720Contributions to Journals: ArticlesComplex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer's Disease
Journal of Pharmacology and Experimental Therapeutics, vol. 352, no. 1, pp. 110-118Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1124/jpet.114.219352
Tau-aggregation inhibitor therapy for Alzheimer's disease
Biochemical Pharmacology, vol. 88, no. 4, pp. 529-539Contributions to Journals: ArticlesTauRx global phase 3 trial in Alzheimer's disease with tau aggregation inhibitor LMTX
13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, pp. S26Contributions to Journals: Abstracts- [ONLINE] DOI: https://doi.org/10.1016/j.neurobiolaging.2014.01.128
Calcyclin binding protein and Siah-1 interacting protein in Alzheimer's disease pathology: neuronal localization and possible function
Neurobiology of Aging, vol. 34, no. 5, pp. 1380-1388Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/j.neurobiolaging.2012.11.007
New phenothiazine diaminium compounds are tau protein aggregation inhibitors, useful to treat e.g. Alzheimer's disease, Pick's disease, progressive supranuclear palsy, frontotemporal dementia and frontotemporal lobar degeneration syndromes
Patents: PatentsThe molecular pathology of Alzheimer's disease
Neuroimaging Clinics of North America, vol. 22, no. 1, pp. 11-22Contributions to Journals: Literature Reviews- [ONLINE] DOI: https://doi.org/10.1016/j.nic.2011.11.003
3,7-diamino-10H-phenothiazine salts and their use: WO2007110627
Patents: PatentsStripline resonator and preamplifier for preclinical magnetic resonance imaging at 4.7 T
Magnetic Resonance Materials in Physics, Biology and Medicine, vol. 24, no. 6, pp. 331-337Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1007/s10334-011-0273-8
3,6-Disubstituted xanthylium salts
Patents: PatentsMethods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC): methods of treatment of a tauopathy condition comprising the use of thioninium compounds
Patents: PatentsLigands for aggregated tau molecules: WO2010034982
Patents: PatentsRationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies
Emerging drugs and targets for Alzheimer's disease: Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism. Martinez, A. (ed.), pp. 210-232, 23 pagesChapters in Books, Reports and Conference Proceedings: ChaptersLewy body variant of Alzheimer's disease: selective neocortical loss of t-SNARE proteins and loss of MAP2 and alpha-synuclein in medial temporal lobe
The Scientific World Journal, vol. 9, pp. 1463-1475Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1100/tsw.2009.151
What is the molecular pathology that underlies hippocampal memory decline?
Journal of Neurology, Neurosurgery & Psychiatry, vol. 80, no. 7, pp. 703Contributions to Journals: EditorialsTherapeutic Use of Diaminophenothiazines: WO2009044127
Patents: PatentsMethylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine
Psychopharmacology, vol. 202, no. 1-3, pp. 53-65Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1007/s00213-008-1394-2
Thiazin red as a neuropathological tool for the rapid diagnosis of Alzheimer's disease in tissue imprints
Acta Neuropathologica, vol. 116, no. 5, pp. 507-515Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1007/s00401-008-0431-x
Inhibitors of protein aggregation: WO2007110629
Patents: PatentsCharacteristics of neuronal lipofuscin in the superior temporal gyrus in Alzheimers disease do not differ from non-diseased controls: a comparison with disease-related changes in the superior frontal gyrus
Acta Neuropathologica, vol. 109, no. 5, pp. 490-496Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1007/s00401-005-0993-9
Inhibition of tau-tau-association
Patents: PatentsAlzheimer's disease
The Oxford Companion to The Mind. Gregory, R. (ed.). 2 edition. Oxford University Press, pp. 24-27, 4 pagesChapters in Books, Reports and Conference Proceedings: ChaptersNaphthoquinone-type inhibitors of protein aggregation
Patents: PatentsMaterials and methods relating to protein aggregation in neurodegenerative disease: WO2002059150
Patents: PatentsLoss of synaptic but not cytoskeletal proteins in the cerebellum of chronic schizophrenics
Neuroscience Letters, vol. 317, no. 3, pp. 161-165Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/S0304-3940(01)02458-2
Inhibition of tau-tau-association
Patents: PatentsMaterials and methods relating to protein aggregation in neurodegenerative disease: WO2002055720
Patents: PatentsNeurofibrillary labels
Patents: PatentsAccumulation of C-terminally truncated tau protein associated with vulnerability of the perforant pathway in early stages of neurofibrillary pathology in Alzheimer’s disease
Journal of Chemical Neuroanatomy, vol. 22, no. 1-2, pp. 65-77Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/S0891-0618(01)00096-5
Loss of synaptic, but not cytoskeletal proteins in the cerebellum of people with chronic schizophrenia
Schizophrenia Research, vol. 49, no. Suppl. 1, pp. 55Contributions to Journals: Abstracts- [ONLINE] DOI: https://doi.org/10.1016/S0920-9964(01)00159-1
The molecular basis of tau protein pathology in Alzheimer's Disease and related neurodegenerative dementias
Neurobiology of Alzheimer’s Disease. Dawbarn, D., Allen, S. (eds.). 2 edition. Oxford University PressChapters in Books, Reports and Conference Proceedings: ChaptersDementia with Lewy bodies
The Encyclopedia of Aging. A Comprehensive Resource in Gerontology and Geriatrics, 3rd Edition. G.L. Maddox, et al., Editors. Springer Publishing Company, New York, pp. 280-282, 2 pagesChapters in Books, Reports and Conference Proceedings: ChaptersPrion diseases
The Encyclopedia of Aging: A Comprehensive Resource in Gerontology and Geriatrics. Maddox, G. (ed.). 3 edition. Springer, pp. 817-819, 3 pagesChapters in Books, Reports and Conference Proceedings: Chapters